F2 Ventures

ReNAgade Therapeutics specializes in RNA therapeutics, focusing on its vast potential to treat diseases. The company's comprehensive RNA platform enables coding, editing, and gene insertion using an all-RNA system for developing new medications.

4M Analytics is a geo-data company specializing in subsurface infrastructure mapping. It has developed a sophisticated mapping engine that serves utility and infrastructure construction projects, particularly during the pre-planning and planning phases. This technology leverages artificial intelligence and analytics to analyze satellite and aerial imagery, allowing for the creation of detailed and accurate subsurface infrastructure maps. These maps can be generated remotely and do not require prior as-built data, making it possible to provide insights anywhere in the world at an unprecedented scale and low cost. The company's platform enhances location intelligence by identifying both known and unknown utilities or infrastructure, thereby maximizing efficiency and reducing the risks of delays, budget overruns, and safety issues in construction projects.

AlloVir is a biopharmaceutical company focused on developing allogeneic T-cell therapies to combat viral diseases. Its proprietary virus-specific T cell (VST) therapy platform enables the creation of off-the-shelf VSTs, designed to restore immunity in patients with T cell deficiencies at risk from life-threatening viral infections.

Justt is a company that specializes in chargeback mitigation solutions for eCommerce merchants. It has developed an automated platform that utilizes artificial intelligence technology to combat illegitimate chargebacks. This platform is designed to streamline the process for merchants by offering an intuitive user dashboard, allowing them to easily track the status of their chargebacks. By leveraging this technology, Justt enables businesses to implement effective strategies to recover lost funds resulting from chargebacks.

Founded in 2017, Five Sigma develops a cloud-native SaaS platform for automating claims management processes in the insurance industry. Its solution uses AI/ML capabilities to simplify claims processing, improve adjuster decision-making, reduce errors and leakage, enhance compliance, and boost customer experience.

4M Analytics is a geo-data company specializing in subsurface infrastructure mapping. It has developed a sophisticated mapping engine that serves utility and infrastructure construction projects, particularly during the pre-planning and planning phases. This technology leverages artificial intelligence and analytics to analyze satellite and aerial imagery, allowing for the creation of detailed and accurate subsurface infrastructure maps. These maps can be generated remotely and do not require prior as-built data, making it possible to provide insights anywhere in the world at an unprecedented scale and low cost. The company's platform enhances location intelligence by identifying both known and unknown utilities or infrastructure, thereby maximizing efficiency and reducing the risks of delays, budget overruns, and safety issues in construction projects.

Orna Therapeutics is a biotechnology company focused on designing and delivering fully engineered circular RNA (oRNA) therapeutics. Its platform combines engineered circular RNA constructs that drive protein expression with delivery solutions, notably lipid nanoparticles, to enable safe and effective in vivo therapies. The approach expands therapeutic possibilities across diseases such as oncology, autoimmune diseases, and infectious diseases. Established in 2019 and based in Cambridge, Massachusetts, Orna Therapeutics pursues therapies built on oRNA constructs designed to express therapeutic proteins in a controlled manner.

Cullinan Therapeutics is a developer of an externally sourced cancer therapeutics intended to end a drug program quickly if the early research suggests it won't work. The company's therapeutics are developed via assets sourced internally through dry lab or externally through business, academic and pharma collaborations, enabling researchers to get a highly diversified portfolio of oncology therapeutics with a unique, cost-efficient business model.

Cullinan Therapeutics is a developer of an externally sourced cancer therapeutics intended to end a drug program quickly if the early research suggests it won't work. The company's therapeutics are developed via assets sourced internally through dry lab or externally through business, academic and pharma collaborations, enabling researchers to get a highly diversified portfolio of oncology therapeutics with a unique, cost-efficient business model.

Founded in 2017, ElevateBio operates a portfolio of companies focused on developing, manufacturing, and commercializing transformative cell and gene therapies for severe diseases. Through strategic partnerships with leading scientists and inventors, along with a centralized facility for efficient translation of R&D into viable therapies, the company aims to deliver life-changing medicines to patients.

AlloVir is a biopharmaceutical company focused on developing allogeneic T-cell therapies to combat viral diseases. Its proprietary virus-specific T cell (VST) therapy platform enables the creation of off-the-shelf VSTs, designed to restore immunity in patients with T cell deficiencies at risk from life-threatening viral infections.

TriNetX, Inc. operates a global health research network that facilitates clinical research and enhances the discovery of new therapies. The company provides a suite of tools, including TriNetX Live for analyzing patient populations, TriNetX Research for accessing longitudinal clinical data, and TriNetX Download for obtaining real-world clinical data through a unified platform. Additionally, TriNetX offers Attract Trials to streamline collaboration, Natural Language Processing to extract clinical information from physician notes, and specialized oncology solutions to link researchers with clinical and genomic data. Serving healthcare organizations, biopharmaceutical companies, and contract research organizations, TriNetX aims to optimize clinical trial design and recruitment, improving the speed and efficiency of bringing new therapies to market. Established in 2013, the company is headquartered in Cambridge, Massachusetts, with additional offices in Sydney, London, and Sao Paulo.

TCR2 Therapeutics Inc., a clinical-stage immunotherapy company based in Cambridge, Massachusetts, focuses on developing novel T cell receptor therapies for cancer treatment. Founded in 2015 by Dr. Patrick Baeuerle and MPM Capital, TCR2 specializes in engineering T cells to target specific antigens expressed by cancer cells. The company's lead product candidates include TC-210, which targets mesothelin-positive solid tumors such as non-small cell lung cancer (NSCLC), ovarian cancer, malignant pleural/peritoneal mesothelioma, and cholangiocarcinoma; and TC-110, targeting CD19-positive B-cell hematological malignancies. TCR2's pipeline also includes candidates for adult acute lymphoblastic leukemia, diffuse large B-cell lymphoma, and follicular lymphoma. The company's approach is distinct from traditional CAR-T cells and other engineered T cell therapies, leveraging a deep understanding of T cell receptor biology to create highly differentiated treatments.

Cullinan Therapeutics is a developer of an externally sourced cancer therapeutics intended to end a drug program quickly if the early research suggests it won't work. The company's therapeutics are developed via assets sourced internally through dry lab or externally through business, academic and pharma collaborations, enabling researchers to get a highly diversified portfolio of oncology therapeutics with a unique, cost-efficient business model.

TCR2 Therapeutics Inc., a clinical-stage immunotherapy company based in Cambridge, Massachusetts, focuses on developing novel T cell receptor therapies for cancer treatment. Founded in 2015 by Dr. Patrick Baeuerle and MPM Capital, TCR2 specializes in engineering T cells to target specific antigens expressed by cancer cells. The company's lead product candidates include TC-210, which targets mesothelin-positive solid tumors such as non-small cell lung cancer (NSCLC), ovarian cancer, malignant pleural/peritoneal mesothelioma, and cholangiocarcinoma; and TC-110, targeting CD19-positive B-cell hematological malignancies. TCR2's pipeline also includes candidates for adult acute lymphoblastic leukemia, diffuse large B-cell lymphoma, and follicular lymphoma. The company's approach is distinct from traditional CAR-T cells and other engineered T cell therapies, leveraging a deep understanding of T cell receptor biology to create highly differentiated treatments.

iPrice Group is an online price comparison platform that aims to enhance the e-commerce experience for shoppers in Southeast Asia by offering a diverse selection of products from numerous online retailers. The company provides users with the ability to compare prices, discover various products, and find the best deals across multiple categories, including electronics, fashion, home improvements, and baby products. By partnering with hundreds of online shops, iPrice facilitates a transparent and convenient shopping experience. Established in Kuala Lumpur, the company has rapidly expanded its presence across seven markets, including Indonesia, Vietnam, Singapore, Hong Kong, Thailand, and the Philippines. With a mission to boost trust and convenience in the e-commerce sector, iPrice leverages international expertise in technology and online marketing to serve its customers effectively.

Clinical Ink, Inc. specializes in providing eSource and patient engagement solutions designed to streamline clinical research for sites, sponsors, contract research organizations (CROs), and patients. Founded in 2006 and headquartered in Horsham, Pennsylvania, with additional offices in Winston-Salem and Cary, North Carolina, Philadelphia, Pennsylvania, and Cambridge, Massachusetts, the company offers a suite of innovative tools including SureSource, an electronic source platform that captures data and documents at the site level, and Lunexis ePRO+, which facilitates patient participation in studies. Additionally, Clinical Ink provides CentrosHealth, a patient engagement platform that includes configurable apps to enhance patient involvement and compliance throughout clinical trials. The company aims to improve clinical trial workflows by integrating electronic data capture and reducing manual processes, ensuring that clients have access to high-quality, validated data.

Chiasma is a biopharmaceutical company specializing in late-stage clinical development. It focuses on transforming injectable drugs into oral medications using its proprietary Transient Permeability Enhancer technology, with a primary focus on treating rare and serious chronic diseases.

ProterixBio, Inc. is a biomedical company based in Billerica, Massachusetts, focused on developing disease management platforms for chronic respiratory diseases. The company specializes in proprietary blood-based biomarker tests aimed at transforming the management of conditions such as chronic obstructive pulmonary disease, cystic fibrosis, and idiopathic pulmonary fibrosis. ProterixBio's ViBE platform, along with its Acoustic Membrane MicroParticle (AMMP) assays, facilitates the precise analysis of proteins in various sample types, delivering real-time biological assessments of a patient's disease state. This technological innovation enhances the sensitivity and specificity of traditional testing methods, allowing healthcare providers to make informed decisions that help reduce hospitalizations and improve patient outcomes, ultimately lowering healthcare costs. Founded in 2002, ProterixBio seeks to address the unmet needs in chronic care management through its advanced diagnostic capabilities.

ProterixBio, Inc. is a biomedical company based in Billerica, Massachusetts, focused on developing disease management platforms for chronic respiratory diseases. The company specializes in proprietary blood-based biomarker tests aimed at transforming the management of conditions such as chronic obstructive pulmonary disease, cystic fibrosis, and idiopathic pulmonary fibrosis. ProterixBio's ViBE platform, along with its Acoustic Membrane MicroParticle (AMMP) assays, facilitates the precise analysis of proteins in various sample types, delivering real-time biological assessments of a patient's disease state. This technological innovation enhances the sensitivity and specificity of traditional testing methods, allowing healthcare providers to make informed decisions that help reduce hospitalizations and improve patient outcomes, ultimately lowering healthcare costs. Founded in 2002, ProterixBio seeks to address the unmet needs in chronic care management through its advanced diagnostic capabilities.

Chiasma is a biopharmaceutical company specializing in late-stage clinical development. It focuses on transforming injectable drugs into oral medications using its proprietary Transient Permeability Enhancer technology, with a primary focus on treating rare and serious chronic diseases.

Chiasma is a biopharmaceutical company specializing in late-stage clinical development. It focuses on transforming injectable drugs into oral medications using its proprietary Transient Permeability Enhancer technology, with a primary focus on treating rare and serious chronic diseases.

ProterixBio, Inc. is a biomedical company based in Billerica, Massachusetts, focused on developing disease management platforms for chronic respiratory diseases. The company specializes in proprietary blood-based biomarker tests aimed at transforming the management of conditions such as chronic obstructive pulmonary disease, cystic fibrosis, and idiopathic pulmonary fibrosis. ProterixBio's ViBE platform, along with its Acoustic Membrane MicroParticle (AMMP) assays, facilitates the precise analysis of proteins in various sample types, delivering real-time biological assessments of a patient's disease state. This technological innovation enhances the sensitivity and specificity of traditional testing methods, allowing healthcare providers to make informed decisions that help reduce hospitalizations and improve patient outcomes, ultimately lowering healthcare costs. Founded in 2002, ProterixBio seeks to address the unmet needs in chronic care management through its advanced diagnostic capabilities.